Form 4: HCA Healthcare EVP Exercises SARs, Sells Shares Under 10b5-1 Plan

HCA Healthcare's EVP and Chief Clinical Officer, Michael S. Cuffe, exercised stock appreciation rights and sold common stock shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Michael S. Cuffe, EVP and Chief Clinical Officer of HCA Healthcare, engaged in transactions involving the company's common stock and stock appreciation rights (SARs).
• On September 4, 2025, Cuffe exercised 10,920 stock appreciation rights (SARs) with an exercise price of $173.12 per share.
• Concurrently, 7,084 shares of common stock were disposed of on September 4, 2025, at a price of $411.59 per share, likely to cover tax liabilities or exercise costs.
• An additional 3,836 shares of common stock were sold on the open market on September 8, 2025, at a price of $418.84 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025.
• Following these transactions, Cuffe beneficially owns 31,502.9017 shares of common stock, which includes 2,595.9017 shares from employee stock purchase plans.
• Cuffe also beneficially owns 10,000 stock appreciation rights after the reported exercise.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an executive selling shares can sometimes be seen negatively, these transactions were pre-planned under a Rule 10b5-1 plan, indicating a scheduled liquidity event rather than a reaction to new, adverse information. The exercise of SARs is a positive for the executive, realizing value from compensation.

Positives

• The exercise of stock appreciation rights indicates the executive is realizing value from previously granted equity compensation.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• The sale of common stock by a high-ranking executive reduces their direct equity stake in the company.

Risks

• The Power of Attorney explicitly states that neither the Company nor the attorneys-in-fact assume liability for the undersigned's responsibility to comply with Exchange Act requirements, any failure to comply, or for profit disgorgement under Section 16(b) of the Exchange Act.
• The Power of Attorney does not relieve the undersigned from responsibility for compliance with obligations under the Exchange Act, including reporting requirements under Section 16.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing instead on executive equity transactions.

Management Comments

• The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.
• The undersigned acknowledges that this Power of Attorney authorizes, but does not require, such attorneys-in-fact to act in their discretion on information provided to such attorneys-in-fact without independent verification of such information.
• This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

Industry Context

This Form 4 filing details routine executive compensation realization and liquidity events, which are common across all industries, including healthcare. The use of a Rule 10b5-1 plan is a standard practice for executives to manage personal finances while adhering to insider trading regulations.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even if planned, slightly reduces management's direct alignment with shareholder interests through equity ownership. However, the pre-planned nature mitigates concerns about adverse signals.
• Employees: The filing details executive compensation realization, which is part of the broader compensation structure for key personnel.

Next Steps

• Continued compliance with SEC reporting requirements for future transactions by Michael S. Cuffe.
• The remaining 10,000 Stock Appreciation Rights held by Michael S. Cuffe may be exercised before their expiration date of February 3, 2031.

Key Dates

Recommendation

The filing details routine executive equity transactions executed under a pre-arranged 10b5-1 plan. These transactions, involving the exercise of stock appreciation rights and subsequent sale of shares for liquidity and tax purposes, are expected and do not signal any new fundamental changes to the company's prospects. Therefore, the filing itself does not provide a basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this information.

Keywords

HCA Healthcare, HCA, Form 4, Insider Trading, Stock Appreciation Rights, SARs, Executive Compensation, Rule 10b5-1, Stock Sale, Officer Transaction, Healthcare